Pathophysiology
B-cell receptor signalling drives clonal survival; genetic aberrations (del(17p)/TP53, del(11q), IGHV unmutated) predict worse prognosis.
Sources: iwCLL 2018 (Blood 2018;131:2745); NEJM Acalabrutinib 2020;383:432
Presentation
Often asymptomatic lymphocytosis; painless lymphadenopathy, splenomegaly, fatigue, autoimmune haemolytic anaemia, ITP; recurrent infections.
Diagnosis
Absolute B lymphocyte count >=5x10^9/L with characteristic immunophenotype (CD5+, CD19+, CD23+, kappa/lambda restricted). Smudge cells on peripheral smear.
Management
Watch-and-wait if asymptomatic. Treatment triggers (Rai/Binet advanced, cytopenia, bulky nodes): first-line BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) or venetoclax-obinutuzumab; consider TP53 testing.





